{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:04:19Z","timestamp":1790370259248,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymgme.2026.110237","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:02:31Z","timestamp":1787727751000},"page":"110237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Functional characterization of 42 GAA missense variants using a validated in vitro cellular functional assay"],"prefix":"10.1016","volume":"149","author":[{"given":"Shelly","family":"Goomber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Huggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine W.","family":"Rehder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory E.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hye","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Doxey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorva K.","family":"Iyengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica B.","family":"Nading","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha S.","family":"Bali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2026.110237_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"Alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe\u2019s disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2026.110237_bb0010","series-title":"The Metabolic and Molecular Basis of Inherited Disease","first-page":"3389","article-title":"Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.ymgme.2026.110237_bb0015","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-7-73","article-title":"Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study","volume":"7","author":"De Vries","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110237_bb0020","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe disease: early diagnosis and early treatment make a difference","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr. Neonatol."},{"key":"10.1016\/j.ymgme.2026.110237_bb0025","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2015.10.078","article-title":"very early treatment for infantile-onset Pompe disease contributes to better outcomes","volume":"169","author":"Yang","year":"2016","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2026.110237_bb0030","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2026.110237_bb0035","article-title":"Early enzyme replacement therapy in late-onset Pompe disease diagnosed by newborn screening","author":"Case","year":"2026","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110237_bb0040","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1042\/bj2720493","article-title":"Characterization of the human lysosomal alpha-glucosidase gene","volume":"272","author":"Hoefsloot","year":"1990","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2026.110237_bb0045","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","article-title":"Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation","volume":"268","author":"Wisselaar","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2026.110237_bb0050","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1074\/jbc.M404008200","article-title":"Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor","volume":"280","author":"Moreland","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"Pt 3","key":"10.1016\/j.ymgme.2026.110237_bb0055","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1042\/bj2890681","article-title":"Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites","volume":"289","author":"Hermans","year":"1993","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2026.110237_bb0060","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/hmg\/3.12.2231","article-title":"Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation","volume":"3","author":"Huie","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2026.110237_bb0065","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/hmg\/5.7.995","article-title":"A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II)","volume":"5","author":"Raben","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2026.110237_bb0070","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1002\/humu.20745","article-title":"Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating","volume":"29","author":"Kroos","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2026.110237_bb0075","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/humu.21121","article-title":"The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase","volume":"30","author":"Flanagan","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2026.110237_bb0080","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/humu.22108","article-title":"Update of the pompe disease mutation database with 60 novel GAA sequence variants and additional studies on the functional effect of 34 previously reported variants","volume":"33","author":"Kroos","year":"2012","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2026.110237_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1001154","article-title":"Development of a clinically validated in vitro functional assay to assess pathogenicity of novel GAA variants in patients with Pompe disease identified via newborn screening","volume":"13","author":"Goomber","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.ymgme.2026.110237_bb0090","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","article-title":"Measurement of protein using bicinchoninic acid","volume":"150","author":"Smith","year":"1985","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2026.110237_bb0095","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3389","article-title":"Glycogen storage disease type II: acid \u03b1-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2000"},{"key":"10.1016\/j.ymgme.2026.110237_bb0100","first-page":"934","article-title":"\u2018Pseudodeficiencies\u2019 of lysosomal hydrolases","volume":"54","author":"Thomas","year":"1994","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2026.110237_bb0105","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s10038-007-0191-9","article-title":"Structural and biochemical studies on Pompe disease and a \u201cpseudodeficiency of acid \u03b1-glucosidase\u201d","volume":"52","author":"Tajima","year":"2007","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2026.110237_bb0110","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/ejhg.2008.34","article-title":"p.[G576S; E689K]: pathogenic combination or polymorphism in Pompe disease?","volume":"16","author":"Kroos","year":"2008","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2026.110237_bb0115","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/mus.21933","article-title":"Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid alpha-glucosidase activity","volume":"43","author":"Bali","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2026.110237_bb0120","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ymgme.2011.06.010","article-title":"Rapid progressive course of later-onset Pompe disease in Chinese patients","volume":"104","author":"Yang","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110237_bb0125","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1212\/WNL.0000000000000163","article-title":"Pearls & Oy-sters: clues to the diagnosis of adult-onset acid maltase deficiency","volume":"82","author":"Beltran Papsdorf","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2026.110237_bb0130","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s10038-019-0603-7","article-title":"Newborn screening for Pompe disease in Japan: report and literature review of mutations in the GAA gene in Japanese and Asian patients","volume":"64","author":"Momosaki","year":"2019","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2026.110237_bb0135","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ajhg.2016.08.016","article-title":"REVEL: an ensemble method for predicting the pathogenicity of rare missense variants","volume":"99","author":"Ioannidis","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2026.110237_bb0140","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cell.2018.12.015","article-title":"Predicting splicing from primary sequence with deep learning","volume":"176","author":"Jaganathan","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ymgme.2026.110237_bb0145","first-page":"39","article-title":"Identification and functional characterization of GAA mutations in Colombian patients affected by Pompe disease","volume":"7","author":"Ni\u00f1o","year":"2012","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2026.110237_bb0150","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/humu.23878","article-title":"GAA variants and phenotypes among 1,079 patients with Pompe disease: data from the Pompe Registry","volume":"40","author":"Reuser","year":"2019","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2026.110237_bb0155","article-title":"Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease","volume":"14","author":"Desai","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymgme.2026.110237_bb0160","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jpeds.2018.02.007","article-title":"Severe cardiac involvement is rare in patients with late-onset Pompe disease and the common c.-32-13T>G variant: implications for newborn screening","volume":"198","author":"Herbert","year":"2018","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2026.110237_bb0165","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ebiom.2019.03.048","article-title":"A genetic modifier of symptom onset in Pompe disease","volume":"43","author":"Bergsma","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymgme.2026.110237_bb0170","article-title":"GAA variants associated with reduced enzymatic activity but lack of Pompe-related symptoms, incidentally identified by exome sequencing","volume":"36","author":"Malekkou","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2026.110237_bb0175","first-page":"65","article-title":"Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany","volume":"20","author":"Hahn","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2026.110237_bb0180","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1002\/ajmg.a.38369","article-title":"Three cases of multi-generational Pompe disease: are current practices missing diagnostic and treatment opportunities?","volume":"173","author":"McIntosh","year":"2017","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2026.110237_bb0185","article-title":"Characterization of immune response in cross-reactive immunological material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy","volume":"20","author":"Desai","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2026.110237_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107715","article-title":"Variant classification for Pompe disease; ACMG\/AMP specifications from the ClinGen lysosomal diseases variant curation expert panel","volume":"140","author":"Goldstein","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110237_bb0195","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110237_bb0200","article-title":"Recommendations for application of the functional evidence PS3\/BS3 criterion using the ACMG\/AMP sequence variant interpretation framework","volume":"12","author":"Brnich","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.ymgme.2026.110237_bb0205","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-018-0461-z","article-title":"Accurate classification of BRCA1 variants with saturation genome editing","volume":"562","author":"Findlay","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2026.110237_bb0210","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41588-018-0122-z","article-title":"Multiplex assessment of protein variant abundance by massively parallel sequencing","volume":"50","author":"Matreyek","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymgme.2026.110237_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2026.109762","article-title":"Lessons from late-onset Pompe disease identified by Newborn screening: a systematic review","volume":"147","author":"Boueri","year":"2026","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110237_bb0220","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/ijns6010004","article-title":"Newborn screening for Pompe disease in Illinois: experience with 684,290 infants","volume":"6","author":"Burton","year":"2020","journal-title":"Int. J. Neonatal. Screen"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226005202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226005202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:39:53Z","timestamp":1790368793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719226005202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":44,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1096719226005202"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110237","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional characterization of 42 GAA missense variants using a validated in vitro cellular functional assay","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110237"}}